{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:06:49Z","timestamp":1753891609074,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a progressive genetic neuromuscular condition affecting spinal motor neurons. The underlying cause of SMA is deletions or mutations in the SMN gene. It is classified into five variants based on age and clinical manifestations of the patient. In this report, we present the case discovery of a four-month-old male patient with SMA type 1, presenting with generalized hypotonia and regression of acquired neurodevelopmental milestones. Our study aims to illustrate, through a case report, the clinical analysis, therapeutic interventions, and progression until the patient\u2019s demise. This aims to share the challenges in managing such patients and the strategies employed in their care plan. By documenting this case, our goal is to contribute to the understanding of SMA type 1 and emphasize the ongoing need for learning effective care strategies.<\/jats:p>","DOI":"10.3389\/fnins.2024.1476977","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:22:48Z","timestamp":1736317368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Spinal muscular atrophy type 1 in the Caribbean: the first case report from the Dominican Republic"],"prefix":"10.3389","volume":"18","author":[{"given":"Mar\u00eda Bel\u00e9n","family":"Mart\u00edn-Sanz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delvis","family":"Lucas-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Colom\u00e9-Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e2103","DOI":"10.1212\/WNL.0000000000207878","article-title":"Systematic literature review of the natural history of spinal muscular atrophy: motor function, scoliosis, and contractures","volume":"101","author":"Aponte Ribero","year":"2023","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/PHM.0000000000002354","article-title":"Spinal muscular atrophy type 1 survival without new pharmacotherapies: two treatment paradigms","volume":"103","author":"Bach","year":"2024","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1051\/medsci\/2020010","article-title":"SMA: from gene discovery to gene therapy","volume":"36","author":"Barkats","year":"2020","journal-title":"Med. Sci."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"CD012120","DOI":"10.1002\/14651858.CD012120.pub2","article-title":"Physical exercise training for type 3 spinal muscular atrophy","volume":"2019","author":"Bartels","year":"2019","journal-title":"Cochrane Database Syst."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41436-020-0754-0","article-title":"Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data","volume":"22","author":"Chen","year":"2020","journal-title":"Genet. Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/nu13072400","article-title":"Nutritional, gastrointestinal and Endo-metabolic challenges in the Management of Children with spinal muscular atrophy type 1","volume":"13","author":"Corsello","year":"2021","journal-title":"Nutrients"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangouloff","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"Day","year":"2022","journal-title":"BMC Pediatr."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1127713","DOI":"10.3389\/fpubh.2023.1127713","article-title":"Rarecare: a policy perspective on the burden of rare diseases on caregivers in Latin America","volume":"11","author":"Dias","year":"2023","journal-title":"Front. Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e020907","DOI":"10.1136\/bmjopen-2017-020907","article-title":"Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives","volume":"8","author":"Farrar","year":"2018","journal-title":"BMJ Open"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1007\/s10072-024-07503-x","article-title":"Exploring variability in cognitive functioning in patients with spinal muscular atrophy: a scoping review","volume":"45","author":"Giannotta","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","article-title":"Survival of patients with spinal muscular atrophy type 1","volume":"131","author":"Gregoretti","year":"2013","journal-title":"Pediatrics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","article-title":"Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy","volume":"31","author":"Gusset","year":"2021","journal-title":"Neuromuscul. Disord."},{"volume-title":"Newborn screening for 5q-linked spinal muscular atrophy: IQWiG reports \u2013 Commission no. S18-02","year":"2020","key":"ref18"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","article-title":"Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States","volume":"12","author":"Lally","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40258-020-00624-2","article-title":"Costs of illness of spinal muscular atrophy: a systematic review","volume":"19","author":"Landfeldt","year":"2021","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/dmcn.14798","article-title":"Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review","volume":"63","author":"Masson","year":"2021","journal-title":"Dev. Med. Child Neurol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e36197","DOI":"10.7759\/cureus.36197","article-title":"Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40273-021-01105-7","article-title":"Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management","volume":"40","author":"Paracha","year":"2022","journal-title":"PharmacoEconomics"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e0230677","DOI":"10.1371\/journal.pone.0230677","article-title":"Diagnostic journey in spinal muscular atrophy: is it still an odyssey?","volume":"15","author":"Pera","year":"2020","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1007\/s00018-020-03492-0","article-title":"Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1)","volume":"77","author":"Perego","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/brainsci13101419","article-title":"Safety and efficacy of Nusinersen and Risdiplam for spinal muscular atrophy: a systematic review and Meta-analysis of randomized controlled trials","volume":"13","author":"Qiao","year":"2023","journal-title":"Brain Sci."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a selective survival of motor Neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/cer-2021-0216","article-title":"How does risdiplam compare with other treatments for types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison","volume":"11","author":"Ribero","year":"2022","journal-title":"J. Comp. Eff. Res."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/jcmm.14874","article-title":"Spinal muscular atrophy with respiratory distress type 1: clinical phenotypes, molecular pathogenesis and therapeutic insights","volume":"24","author":"Saladini","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13023-022-02561-w","article-title":"Carer burden in rare inherited diseases: a literature review and conceptual model","volume":"17","author":"Sandilands","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for Care","volume":"7","author":"Schorling","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1007\/s12325-023-02621-y","article-title":"Health Care resource utilization and costs for patients with spinal muscular atrophy: findings from a retrospective US claims database analysis","volume":"40","author":"Toro","year":"2023","journal-title":"Adv. Ther."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","article-title":"One year of newborn screening for SMA - results of a German pilot project","volume":"6","author":"Vill","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s12325-022-02089-2","article-title":"Systematic literature review of clinical and economic evidence for spinal muscular atrophy","volume":"39","author":"Yang","year":"2022","journal-title":"Adv. Ther."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1476977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:22:51Z","timestamp":1736317371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1476977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":38,"alternative-id":["10.3389\/fnins.2024.1476977"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2024.1476977","relation":{},"ISSN":["1662-453X"],"issn-type":[{"type":"electronic","value":"1662-453X"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1476977"}}